At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Gemcitabine +2 moredrug
Likely dose
Gemcitabine 1000 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Open Label Study of Gemcitabine, Paclitaxel and Bevacizumab Combination as First Line Treatment for Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Gemcitabine, Paclitaxel, and 1 other intervention for Breast Cancer and Metastatic Breast Cancer. Completed, enrolled 31 participants across 1 site.
Detailed Summary
Single-institution phase 2 trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Metastatic Breast Cancer
CountriesUnited States
CollaboratorsGenentech, Inc., Eli Lilly and Company
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedNov 2006
Primary CompletionSep 2010
Study CompletionNov 2012
TodayJul 2026
First PostedNov 23, 2006
Enrollment StartFeb 1, 2006
Primary CompletionSep 1, 2010
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 19.6 years ago
Interventions
Gemcitabinedrug
Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
Paclitaxeldrug
Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
Bevacizumabdrug
Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles